Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on Arrowhead Pharma (NASDAQ:ARWR) and keeps the price target at $60.
June 26, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital analyst Keay Nakae maintains a Buy rating on Arrowhead Pharma and keeps the price target at $60.
The reaffirmation of a Buy rating and a $60 price target by Chardan Capital is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100